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Abstract
Acetaldehyde, the first metabolite of ethanol, is active in the central nervous system, where it exerts motivational properties.
Acetaldehyde is able to induce drinking behaviour in operant-conflict paradigms that resemble the core features of the
addictive phenotype: drug-intake acquisition and maintenance, drug-seeking, relapse and drug use despite negative
consequences. Since acetaldehyde directly stimulates dopamine neuronal firing in the mesolimbic system, the aim of this
study was the investigation of dopamine D2-receptors’ role in the onset of the operant drinking behaviour for acetaldehyde
in different functional stages, by the administration of two different D2-receptor agonists, quinpirole and ropinirole. Our
results show that acetaldehyde was able to induce and maintain a drug-taking behaviour, displaying an escalation during
training, and a reinstatement behaviour after 1-week forced abstinence. Acetaldehyde operant drinking behaviour involved
D2-receptor signalling: in particular, quinpirole administration at 0.03 mg/kg, induced a significant decrease in the number
of lever presses both in extinction and in relapse. Ropinirole, administered at 0.03 mg/kg during extinction, did not produce
any modification but, when administered during abstinence, induced a strong decrease in acetaldehyde intake in the
following relapse session. Taken together, our data suggest that acetaldehyde exerts its own motivational properties,
involving the dopaminergic transmission: indeed, activation of pre-synaptic D2-receptors by quinpirole, during extinction
and relapse, negatively affects operant behaviour for acetaldehyde, likely decreasing acetaldehyde-induced dopamine
release. The activation of post-synaptic D2-receptors by ropinirole, during abstinence, decreases the motivation to the
consecutive reinstatement of acetaldehyde drinking behaviour, likely counteracting the reduction in the dopaminergic tone
typical of withdrawal. These data further strengthen the evidence that acetaldehyde may play a crucial role as mediator of
ethanol’s central effects.
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Introduction
The neurobiological mechanism underlying the pharmacolog-
ical properties of ethanol is complex and not completely elucidated
[1]. In this regard, acetaldehyde (ACD), its first metabolite, has
been increasingly recognized as strongly involved in various
ethanol neuropharmacological, neurobiological and behavioural
effects [2–8]. Despite its reputation as an aversive substance for
long time [9], ACD possesses motivational and reinforcing
properties, highlighted in rodents by different behavioural
paradigms, as place conditioning [10,11] and operant self-
administration [12–15]; protocols which include reinstatement
and conflict procedures have also been reported [16,17].
Dopamine (DA) plays a prominent role in the different stages of
the addiction cycle [18–20]. The dopaminergic (DAergic) trans-
mission represents the neurobiological substrate of the acute
reinforcing properties of the drugs of abuse [21] and of their
enhanced incentive salience [22]. However, the function of the
mesolimbic DA system is severely impaired upon cessation of the
chronic exposure to several drugs of abuse, including ethanol [23].
Acute withdrawal is associated with an increase in reward
thresholds in animals, a finding which mirrors the decreased
activity of the mesolimbic dopamine system observed by electro-
physiological recordings and in vivo microdialysis [24–27].
Furthermore a decrease in the number and function of D2
receptors, observed both in animals [28,29] and in humans [30–
33], is consistent with the hypodopaminergic state in ethanol
withdrawal, and is functionally correlated to the enhancement in
drug craving, drug intake and relapse [34–36].
Several reports clearly show that pharmacological properties of
ACD involve the DAergic system: ACD is able to increase the
neuronal firing of DA neurons in the ventral tegmental area [37],
to stimulate DA release from their projections [38–40] and to
promote, in DA terminal areas, the induction of early-gene protein
expression, as c-Fos, considered as a general marker of neural
activity [41]. Although this general evidence points to the
involvement of mesencephalic DA neurons in ACD neurophar-
macological action, the few studies exploring the neurobiological
mechanisms underlying the reinforcing and addictive-like proper-
ties of oral ACD, have focused on endocannabinoid [17] and
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opioid [42] systems, while DA’s direct contribution to ACD
operant drinking behaviour still remains elusive.
We now hypothesize that ACD-induced operant behaviour can
be modulated by the direct manipulation of DAergic signalling; we
verify our hypothesis by investigating the role of two different D2
receptor agonists, quinpirole and ropinirole, in distinct functional
phases of ACD operant-drinking behaviour. D2 receptors have
both pre- and post-synaptic localization [43–46]: quinpirole, at
low doses, has been reported to preferentially bind to D2
autoreceptors [47,48]. Ropinirole, a post-synaptic D2 agonist, is
already used to restore dopaminergic tone in Parkinson’s Disease
[49,50], as well as in the normalisation of the behavioural
responses to natural rewards in anhedonic states [51]. The
effectiveness of these two different D2 receptors agonists in
reducing drug seeking and drug taking, during extinction and
relapse in ACD-induced operant behaviour, can imply important
translational consequences concerning the pharmacological treat-
ments of alcohol addiction.
Materials and Methods
Ethics Statement
The experimental procedures have been carried out in
accordance with the Italian legislation D.L. 116/1992 and the
EU Directive 2010/63/EU, dealing with research on experimen-
tal animals, and approved by the Committee on the Ethics of
Animal Experiments of the University of Palermo. All efforts were
made to minimize animal suffering.
Animals
Adult male Wistar rats (Harlan, Udine, Italy) (n = 44), weighing
250–300 g, were used in this study. Rats were housed two per cage
(standard rat cages, Tecniplast, Italy) with free access to food,
(standard rodent diet 4RF18, Mucedola, Italy) and tap water, and
kept under controlled environmental conditions (12 h light/dark
cycle, temperature 2262uC, humidity 55610%). Animals were
allowed to habituate to facilities and daily handled before initiation
of the experiments, in order to reduce and minimize animal’s
distress. During operant conditioning experiments, they were
water-restricted and allowed to drink 1 hour/day at the end of the
experimental sessions. Water intake was recorded. For each
experiment, animals were randomly assigned to the different
experimental groups.
Drugs
ACD 99,98% (Sigma-Aldrich SRL, Milan Italy) was stocked at
220uC and the solution was prepared with distilled water daily.
ACD concentration (3.2%; 1.6 ml in 50 ml of solution) was
controlled and measured with UV spectrum analysis, either at the
beginning or at the end of the operant session. The procedure
confirmed that ACD concentration was preserved along the 20-
minute experimental procedure [16].
Quinpirole hydrochloride (Sigma-Aldrich, Milan, Italy), used in
Experiment 1, was dissolved in saline solution (0.9% NaCl), and
administered intraperitoneally (i.p.) (0.03 mg/kg), 30 minutes
prior to start behavioural procedures.
Ropinirole (Sigma-Aldrich, Milan, Italy), used in Experiment 2,
was dissolved in saline solution (0.9% NaCl), and administered
daily during the 7-day deprivation 2 period (0.03 mg/kg, i.p.).
Operant Apparatus
The experimental sessions were carried out in a custom-built
operant-conditioning chamber (30628637 cm), placed in a dim-
illuminated, ventilated, sound-attenuating cubicle. The chamber
solution from evaporation, with a solenoid-actuated delivery
system. It assured the delivery of 0.028 ml of solution for each
lever press. Animal performance was recorded on a counter
connected to the chamber. The devices were thoroughly cleaned
before the introduction of each animal to ensure that the
particular rat’s behaviour was not affected by the detection of
another rat’s scent.
Open Field Arena
Locomotor activity was measured in an Open Field with an
automatic video-tracking system, Any Maze (Ugo Basile, Italy).
The Open Field is a square box, 44 cm long, 44 cm wide, and
20 cm high. The software produces a quali-quantitative mapping
of the motor pattern and measures Total Distance Travelled
(TDT; cm) along 5 min.
Experimental procedures
Timeline. The operant drinking behaviour paradigm in-
cludes consecutive experimental sessions: shaping and training (30
days); deprivation 1 (7 days); relapse 1 (5 days); extinction (1 day);
deprivation 2 (7 days); relapse 2 (5 days).
Shaping and Training. Animals (n = 44) were shaped to
lever press to obtain water on a continuous reinforcement schedule
(fixed ratio 1, FR-1), until they reached the same level of
performance. Afterwards training started and rats orally self-
administered ACD solution in the operant chamber (FR-1) along
30 days. For each tapping, the system delivered 0.028 ml of 3.2%
ACD solution. The number of lever presses was automatically
recorded; ACD intake was measured by multiplying the number of
lever presses by 0.028 ml, and this value corresponded to the
amount of liquid missing from the reservoir at the end of each
session. Animals were tested each day at the same time (9:00 to
14:00).
Deprivation 1. During the first 7-day deprivation period, rats
were left undisturbed in their home cages and received water and
food ad libitum. ACD self-administration was suspended to
achieve a forced abstinence.
Relapse 1. After the first deprivation period, rats were
exposed again to lever pressing in the operant chamber with a
FR-1 response schedule, for 5 days. Responses were then recorded
during the 20 min-experimental sessions. ACD solution intake was
also recorded.
Experiment 1: administration of quinpirole during
extinction and relapse 2. After the first relapse paradigm,
the effect of quinpirole on ACD operant drinking behaviour was
tested during extinction and relapse 2.
Extinction. Animals underwent an operant responding ses-
sion during which reward delivery was withheld, in order to test
the effect of the pharmacological manipulation on ACD-seeking
behaviour. The number of lever presses throughout the 20-min
session was tracked. During extinction, rats were administered
with 0.03 mg/kg quinpirole (Q-group, n = 8), or vehicle (Vh-
group, n = 8), 30 minutes before entering the operant chamber.
Deprivation 2. ACD self-administration was suspended
again for 7 days to achieve a forced abstinence. Rats were left
undisturbed in their home cages and received water and food ad
libitum.
Relapse 2. During this phase, the two experimental groups
(n = 8 each) were not treated at relapse day 1, in order to have a
baseline value of drinking following abstinence. From day 2 to day
4, they were administered i.p. with 0.03 mg/kg quinpirole, or
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was equipped with one active lever and a cup that collected liquid
from a corked reservoir, aiming at the preservation of ACD
vehicle, according to their group, 30 minutes prior starting the
operant session. Administrations were suspended during session 5.
The dose of Quinpirole was selected because of its capability to
reduce ethanol self-administration in an analogous procedure [47].
In order to test the specificity of quinpirole effect on the operant
response, a water-drinking group (n = 8) was used and subjected to
the same experimental procedures than ACD-drinking rats.
Experiment 2: administration of ropinirole during
extinction and deprivation. After the first relapse paradigm,
the effect of ropinirole on ACD operant drinking behaviour was
tested during the extinction and relapse 2 phases.
Extinction. Animals (n = 20) underwent an operant respond-
ing session during which reward delivery was suspended, in order
to test the effect of the pharmacological manipulation on ACD-
seeking behaviour. The number of lever presses at the end of the
20 min session was recorded. During extinction, rats were
administered with 0.03 mg/kg ropinirole (R-group, n = 10) or
vehicle (Vh-group, n = 10), 30 minutes before getting in the
operant chamber.
Deprivation 2. During this session the distinct groups
received ropinirole (0.03 mg/kg, i.p.), or vehicle, once daily at
the same time (11:00 a.m.) along 7 days.
Relapse 2. During this phase animals received no adminis-
tration. The number of lever presses and the amount of ACD
consumed was measured after each 20-min session.
Open Field Test. Quinpirole and ropinirole effects on
locomotor activity were also tested in the Open Field Test. Rats
(n = 36) were administered with quinpirole (0.03 mg/kg, i.p.),
ropinirole (0.03 mg/kg, i.p.) or vehicle, 30 minutes before entering
the open field arena. Total distance travelled (TDT) at the end of
the 5-minute session was measured.
Statistical analysis
A one-way analysis of variance (ANOVA) for repeated measures
was conducted in order to evaluate the effect of time on the
number of lever presses during training and relapse, while a two-
way ANOVA for repeated measures was employed to assess the
effect of time and treatment on the number of responses emitted
during relapse. Furthermore, in order to compare ACD intake
during the different periods of training, and the effect of quinpirole
and ropinirole treatments on ACD-seeking behaviour during
extinction, and on locomotor activity, a two-tailed Student’s t-test
for unpaired measures was used. When necessary, simple main
effects and post hoc comparisons were calculated with Bonferroni
post-test (a= 0.05). Differences were considered statistically
significant if p,0.05. Data are reported as mean 6 SEM.
Statistical analysis was conducted by using the GraphPad Prism
software, v.6.1 (GraphPad Software, San Diego, CA, USA) on
data from all experimental animals used.
Results
Operant Self-Administration
Training Period. Rats readily acquired 3.2% ACD oral self-
administration within the Training period, progressively increas-
ing the number of lever presses along time. The results of a one-
way ANOVA for repeated measures, showed a significant effect of
time on the number of responses emitted (F(29, 1015) = 68.02, p,
0.0001) (Fig.1A).
In particular, during the first 10 days of exposure to ACD, rats
showed a lower number of lever presses, and consequently an
average intake of 444,16124,3 mg/kg. In the second ten days of
the paradigm, ACD rats’ drinking behaviour increased, displaying
a higher number of lever presses and greater liquid intake, and an
significantly with respect to the previous days, reaching a mean
value of 665,36118,8 mg/kg.
When ACD intake within the three subsequent training periods
was analyzed by a two-tailed Student’s t-test for paired measures, a
significant difference in the amount of ACD consumed in period
III with respect to period I and period II (t = 7.705, df = 9, p,
0.001; t = 2.470, df = 9, p,0.0356) was observed (Fig.1B).
No differences were observed in body weight and water intake
during the free-drinking hour at the end of the experimental
sessions, along the 30-day training period between the two groups.
Relapse 1. Following the first 7 days of abstinence from ACD
self-administration, rats were tested in the operant chamber to
assess whether deprivation could influence their drinking behav-
iour. A one-way ANOVA for repeated measures showed a
statistically significant effect of days on the number of responses
emitted (F(4, 140) = 6.188, p = 0.0001). Bonferroni post-hoc analysis
evidenced a significant increase in number of lever presses in day 2
with respect to day 3 (t = 4.789, df = 140, p,0.001) and day 5
(t = 3.483, df = 140, p,0.01).
Experiment 1: administration of quinpirole during
extinction and relapse 2.
’
Relapse 2. The results of a 2-way ANOVA for repeated
measures including "Quinpirole Treatment" as the between-
subjects factor and ‘‘Days’’ as within-subjects factor showed a
significant effect of time, treatment, and their interaction on the
number of responses emitted, F(4, 56) = 88.05, p,0.0001; F(1, 14)
= 26.10, p = 0.0002; F(4, 56) = 18.95, p,0.0001. Bonferroni post
hoc analysis showed that quinpirole was able to induce a reduction
in the number of lever presses with respect to vehicle in 2 out of 3
days of administration: day 2 (t = 5.883, df = 70, p,0.0001), day 3
(t = 6.991, df = 70, p,0.0001); the two ACD-drinking groups
showed no statistically significant differences in days 1 and 5, when
quinpirole was not administered (Fig. 3A).
Quinpirole effect was also analyzed within the treated group
day by day. The results of a one-way ANOVA for repeated
measure, including "quinpirole treatment" as the between columns
factor, showed a statistically significant effect of the drug on the
amount of ACD consumed (F(1.490, 10.43) = 60.60, p,0.0001).
Bonferroni post hoc analysis showed that quinpirole administra-
tion decreased the amount of ACD ingested in day 2 (t = 7.933,
df = 7, p,0.001); 3 (t = 6.736, df = 7, p,0.01) and 4 (t = 9.242,
df = 7, p,0.001) with respect to day 1, and also when compared to
day 5, when quinpirole administration was suspended (day 2:
t = 8.311, df = 7, p,0.001; day 3: t = 7.504, df = 7, p,0.01; day 4:
t = 9.994, df = 7, p,0.001). No significant difference in mg/kg of
ACD consumed was observed between day 5 and day 1 (Fig. 3B).
When quinpirole was administered in controls, i.e. water-
drinking rats, the results of a 2-way ANOVA for repeated
measures showed no significant effect on the number of lever
presses emitted along the experimental days (F(4,24) = 1.405,
p = 0.2623).
Experiment 2: administration of ropinirole during
extinction and deprivation 2.
Extinction. Rats were tested on the operant condition
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average intake of 543,26144,8 mg/kg. During the last 10-day
period of training, rats’ lever presses for ACD increased
Extinction. Rats were tested in the operant condition
respect to vehicle along the 20 min experimental session (Fig. 2).
in the number of lever presses (t = 2.740, df = 14, p = 0.0160) with
that quinpirole administration induced a significant reduction
Student s t-test for unpaired measures. Our data indicated
number of non-rewarded lever presses was analyzed by a two-tailed
reward delivery was suspended. The effect of quinpirole on the
paradigm to assess quinpirole effect on drug seeking when
reward delivery was suspended. The effect of ropinirole treatment
on non-rewarded lever presses was analyzed by a two-tailed
Student’s t-test for unpaired measures. Our data indicated that
ropinirole treatment, 30 minutes before the extinction session,
was ineffective and no significant difference in the number of
lever presses was observed (t = 0.09720, df = 18, p=0.9236),
compared to vehicle (Fig.4).
Relapse 2. Following 7 days of abstinence from ACD self-
administration in deprivation 2, rats were administered daily with
0.03 mg/kg ropinirole, and were tested again in the operant
chamber to assess whether the treatment could influence their
drinking behaviour in relapse 2. The results of a 2-way ANOVA
for repeated measures including "Ropinirole treatment" as the
between-subjects factor and ‘‘Days’’ as within-subjects factor,
showed a significant effect of time, treatment, and their interaction
on the number of responses emitted (F(4, 72) = 105.2, p,0.0001;
F(1, 18) = 36.11, p,0.0001; F(4, 72) = 2.926, p = 0.0267). Bonferroni
post hoc analysis showed that ropinirole-treated group displayed a
decrease in the number of lever presses in all days of relapse, on
day 1, 2, 3, 4 and 5 (t = 4.047, df = 90, p = 0.0005; t = 4.800,
df = 90, p,0.0001; t = 6.774, df = 90, p,0.0001; t = 3.991,
df = 90, p = 0.0007; t = 4.516, df = 90, p,0.0001) when compared
to vehicle (Fig. 5A).
Accordingly, a two-tailed Student’s t-test for unpaired measures
showed a significant reduction in the amount of ACD in ropinirole
-treated group, with respect to vehicle (t = 5.617, df = 18, p,0.001)
(Fig. 5B).
Open Field Test
The effects of quinpirole and ropinirole treatment on locomo-
tion in terms of TDT in the Open Field Test were analyzed by a
two-tailed Student’s t-test for unpaired measures. Our data
indicate that quinpirole administration induced a significant
reduction in TDT (t = 10.93, df = 14, p,0.0001) with respect to
vehicle (Fig. 6). Ropinirole administration induced no variation in
TDT (t = 1.147, df = 18, p = 0.2665) with respect to vehicle (Fig. 7).
Discussion
The aim of the present study was to investigate the neurophar-
macological basis underpinning discrete aspects of operant
drinking behaviour for ACD in male rats.
Previous self-administration studies demonstrated that ACD
possesses its own reinforcing and motivational properties
[10,15,52,53] since it is able to induce and maintain an operant
behaviour in rats and promotes different drug-related behaviours,
such as resilience to extinction, induction to relapse and to
compulsive-like behaviour [12,16,17]. Recent works by Karaha-
nian and colleagues elegantly demonstrated that ACD has a
crucial role in mediating ethanol reinforcement in the VTA.
Indeed, reducing ACD generation, or increasing its metabolism in
the VTA, can lead to a marked reduction of ethanol intake in
naive rats [5,54], but the increase in ACD metabolism in VTA
failed to affect ethanol intake in animals that consumed ethanol
chronically for 2–3 months [54]. In this regard, a role for high
ACD peripheral levels, able to cross the blood-brain barrier,
cannot be ruled out. Since chronic ethanol exposure leads to
CYP2E1 induction and decreased activity of aldehyde dehydro-
genase [55–58], it is worth exploring the pharmacological
potential properties of peripheral ACD, which may also account
for its positive reinforcing effects. Remarkably, some of the
behavioural features of orally self-administered ACD are sensitive
to the pharmacological modulation of the cannabinoid CB1
receptor [17], as well as of the opioid neurotransmission [42].
These systems are largely involved in the induction of alcohol
drinking behaviour and relapse [59,60,35] and can likely influence
ACD drinking behaviour through the modulation of the DAergic
Figure 1. Operant drinking-behaviour pattern. Number of lever presses during the 30 days of training in the operant-drinking paradigm (A).
ACD consumption (mg/kg) during subsequent periods of training in the operant-drinking paradigm. up,0.001 Vs period I; *p,0.05 vs period II (B).
doi:10.1371/journal.pone.0099454.g001
Figure 2. Quinpirole and Extinction. Number of lever presses
during the 20-min Extinction session, in vehicle (Vh) - and quinpirole (Q)
treated rats. *p,0.05 Vs Vh.
doi:10.1371/journal.pone.0099454.g002
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paradigm to assess ropinirole effect on drug seeking when 
reward pathway, thus causing DA release in the nucleus
accumbens [61].
In the current experiments, the induction of ACD drinking
behaviour was acquired along 30 days. Our data show that in the
last period of training, rats’ ACD intake was significantly higher
than in the previous weeks suggesting that the incentive motivation
for the substance had also been increasing along time [62].
Operant conditioning is a behavioural paradigm specifically
tailored to reflect the measure of the reinforcing properties of
self-administered drugs [63–68]. Chronic exposure to relative high
ACD concentrations, as those used in the present study (3.2%),
aims at creating conditions for ACD central accumulation, since
this small molecule can be found in the central nervous system
when administered i.p. at doses of 100 mg/kg [69,70]. According
to our data, ACD intake reached mean values of 665,3 mg/kg,
within the 20 min-operant session, and it is conceivable that such
chronic and increasing intake of ACD can overwhelm the
metabolic barrier constituted by epithelial aldehyde dehydroge-
nase (ALDH1), a low Km ACD-oxidizing enzyme expressed in
gastrointestinal tract [71]. Systemic absorption after ACD oral
ingestion has been already demonstrated by previous studies on
ACD self-administration by Peana and colleagues [12]. Therefore,
increasing blood ACD concentrations could saturate the moderate
aldehyde dehydrogenase activity of BBB capillaries [72–74,8],
enter the brain, and exert central activity.
Our results are in agreement with previous data from this
laboratory [16], and can be ascribed to the rewarding and
motivational properties of ACD. Animals easily self-administer
ACD [13–16], likely as a consequence of its reinforcing properties,
reported to be 1000-fold stronger than ethanol’s [15,53]. Although
apparently in opposition with reports on primarily ACD aversive
effects following acute peripheral administration [75], our results
must be interpreted in the context of the particular experimental
protocol. ACD operant-drinking behaviour is induced and
maintained along a relatively long period, which is likely required
for exerting pharmacologically significant central effects. On the
other hand, our findings are in line with early studies reporting
positive euphoric effects following moderate consumption of
ethanol in subjects treated with aldehyde dehydrogenase inhibi-
tors, such as disulfiram [76].
DA involvement in the operant behaviour for ACD was assessed
by using quinpirole and ropinirole, DA D2 receptor-selective
ligands with a different pharmacodynamic profile, whose admin-
istration aimed at selectively modulate the DAergic synapse in
different functional states. Indeed, the rationale of the experiment
was that quinpirole, administered during extinction and relapse,
could phasically inhibit DAergic signalling, as a consequence of its
activity as agonist at D2 receptors in the presynaptic terminal, and
reduce thus drug-seeking behaviour; ropinirole, on the other hand,
as a D2-D3 receptor agonist, was administered daily during the
deprivation period in order to stimulate the DAergic post-synaptic
terminal, thus reducing the craving for the substance during
reinstatement.
Our data clearly show that, when tested during extinction,
quinpirole acute administration was able to decrease the number
of lever presses, when compared with vehicle. Lever pressing is
thought to reflect learned processes related to motivation to seek
the substance [77] and it is to be considered as a measure of
appetitive ‘‘ACD seeking-like’’ behaviour, which is in turn related
to the induction of mesolimbic DA release [61].
Our evidence shows that quinpirole, at the doses used in this
study, is responsible for the decrease in the number of lever presses
through the reduction in DA neural firing, obtained by the
Figure 3. Quinpirole and Relapse. Number of lever presses in Vh and Q groups during Relapse following 1 week abstinence. up,0.001 Vs Vh (A).
ACD consumption (mg/kg) during Relapse following 1 week abstinence. **p,0.01; ***p,0.001 Vs Vh (B).
doi:10.1371/journal.pone.0099454.g003
Figure 4. Ropinirole and Extinction. Number of lever presses
during the 20-min Extinction session, in vehicle (Vh) - and ropinirole (R)
treated rats.
doi:10.1371/journal.pone.0099454.g004
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activation of D2 pre-synaptic receptors [45,46], indicating that
ACD-seeking behaviour directly depends on DA neurotransmis-
sion.
In order to assess the role of dopamine neurotransmission on
the reinstatement of ACD consumption following a period of
forced abstinence, quinpirole was administered during relapse. In
particular, along the relapse experiment, animals were adminis-
tered with quinpirole during day 2, 3 and 4, in order to consider
day 1 as a reference of the baseline drinking behaviour, and to
evaluate drinking behaviour restoration, once the administration
ceased at day 5.
Quinpirole was able to decrease the number of responses
emitted and, induced a significant reduction in ACD intake, within
the quinpirole treated group, when compared with the first and
the last relapse days. Accordingly, the dose of quinpirole used in
these experiments has previously been shown to decrease ethanol-
reinforced responding [47], likely by disrupting dopamine
transmission, via pre-synaptic receptors stimulation [48,78,79].
It has long been known that activation of D2-like receptors
hyperpolarizes DA neurons and inhibits their firing activity [80–
82]. Consistent with these data, anatomical studies revealed that
D2-like receptors are predominantly expressed on the dendrites of
DA neurons, where their inhibitory activity plays a predominant
role [83]. Quinpirole, activating D2 pre-synapting autoreceptors,
appears to dissociate the process of primary reinforcement from
processes regulating instrumental response initiation, mainte-
nance, and selection [84], hence leading to a decrease in ACD-
attributed salience, and consequently in the motivation to work for
drug self-administration.
In agreement with previous studies [85–87] and consistently
with the pre-synaptic action exerted, quinpirole reduced locomo-
tor activity in terms of total distance travelled, when tested in the
Open Field. Nevertheless, no differences in rats’ behavioural
reactivity in the operant chamber were observed during the
operant self-administration sessions, ruling out a non-specific effect
of the drug in the reduction of the operant behaviour. Indeed,
when tested on the operant-drinking behaviour for water,
quinpirole did not exert any effect, with respect to vehicle,
highlighting a specific activity on motivation for ACD.
A different activity on the DAergic synapse, i.e. a post-synaptic
receptor modulation, was achieved by ropinirole administration.
Ropinirole is a well-tolerated, selective D2-D3 agonist used in
improving the motor symptoms of Parkinson’s Disease, hence able
to increase DA neurotransmission [49,86,88]. Due to its post-
Figure 5. Ropinirole and Relapse. Number of lever presses in Vh and R groups during Relapse following 1 week abstinence. up,0.001 Vs Vh (A).
ACD consumption (mg/kg) during Relapse following 1 week abstinence. ***p,0.001 Vs Vh (B).
doi:10.1371/journal.pone.0099454.g005
Figure 6. Quinpirole and OF. Effect of quinpirole on the total
distance travelled (TDT) in the open field arena. ***p,0.001 Vs Vh.
doi:10.1371/journal.pone.0099454.g006
Figure 7. Ropinirole and OF. Effect of ropinirole on the total
distance travelled (TDT) in the open field arena.
doi:10.1371/journal.pone.0099454.g007
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junctional activity, ropinirole was administered during extinction
in order to verify whether it was able to affect drug-seeking
behaviour. Our results show that ropinirole failed to induce any
modification in lever pressing. This result is consistent with
ropinirole activity in promoting dopamine signalling, but since
ropinirole is devoid of abuse liability, it was not able, in our
experimental conditions, to modify motivation when lever pressing
was not associated to reinforcement.
The acute administration of low dose-ropinirole did not induce
significant variations in total distance travelled in the Open Field,
when compared to vehicle, confirming a mild D2-D3 receptor
stimulation. On the contrary when high dose-dopamine agonists
are employed, long-lasting alterations in DAergic functions
appear. These are associated with increased locomotor activity
and enhanced DA overflow in brain limbic areas, defined as
behavioural sensitization [89,90].
Abrupt withdrawal from alcohol and other substances of abuse
is associated with a decrease in DAergic neuronal activity [24–
27,91,92]. This effect has been indicated as contributing to the
dysphoric state of abstinence [36], and to the enhancement in drug
intake during relapse [23,34]. Moreover, decreased levels of D2-
D3 receptors in the striatum can be visualized by brain imaging in
abstinent alcoholics: this feature has become a common marker of
addiction in human patients [30,32,93].
On the other hand, manipulation of the D2 receptors seems
effective in reducing drug-intake and relapse: when rodents receive
viral-mediated gene transfer of D2 receptors to the nucleus
accumbens, they display attenuated ethanol consumption [94].
The extent to which a mild D2-D3 stimulation, during
withdrawal, can influence the reinstatement behaviour for ACD,
was thus investigated.
Once acquired a long habit to ACD self-administration, and in
order to be tested for reinstatement, rats underwent forced
abstinence, during which they were daily administered with a low
dose of ropinirole. The subsequent testing for relapse shows that
ropinirole was able to significantly decrease the number of lever
presses for ACD, with respect to vehicle, along the whole relapse
phase. Ropinirole administration during abstinence could provide
a mild stimulation of post-synaptic D2-D3 receptors, overcoming
the dysfunctional reduction in DA neurotransmission associated
with craving and vulnerability to relapse. Our data are in line with
the hypothesis that long lasting ACD self-administration, and
related behaviours, can induce a hypo-DAergic tone during
withdrawal, as already demonstrated for alcohol and other
addictive substances [23], likely induced by a dysfunctional
inhibition of DA VTA neurons [95].
Recent reports demonstrate that ropinirole is able to reduce the
subjective reinforcing effect of cocaine in humans [96,97];
moreover Hoefer et al. [51] showed that ropinirole was able to
counteract the reward deficit in methamphetamine withdrawal in
rats, supporting the hypothesis that activating, rather than
blocking, the DAergic system could help attenuating drug seeking
behaviour [98]. Additional studies need to be undertaken to
evaluate ropinirole efficacy in alcohol relapse in order to suggest its
administration as a pharmacological aid in controlling the chronic
relapsing nature of alcohol abuse.
Conclusions
Taken together, these findings show that the pharmacological
modulation of DA synapse has a direct impact on ACD-related
behaviour. Animals do self-administer ACD, and its oral
consumption, or the associated conditioning context and cues,
exerts a DA-releasing effect, as suggested by the different
sensitivity to distinctly acting D2 agonists. Manipulation of the
D2 signalling represents a promising strategy to finely tune DA
control over alcohol and ACD actions in the brain. Post-synaptic
D2 receptors are involved in the modulation of ACD-induced
phenotypes, since their mild and subchronic activation during
withdrawal is able to affect the subsequent drug seeking and intake
during relapse, Moreover, ropinirole treatment during abstinence
has face validity within the clinical setting, and this enhances the
translational relevance of preclinical animal testing for medications
in treating substance use disorders.
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